Premium
[IC‐P‐041]: SAMPLE SIZES FOR 24‐MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID‐POSITIVE ADULTS
Author(s) -
Reiman Eric M.,
Kuang Xiaoying,
Luo Ji,
Chen Yinghua,
Thiyyagura Pradeep,
Bauer Robert,
Lee Wendy,
Protas Hillary,
Goradia Dhruman D.,
Aisen Paul S.,
Johnson Keith,
Langbaum Jessica B.,
Sperling Reisa A.,
Tariot Pierre,
Jagust William J.,
Weiner Michael,
Chen Kewei
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.2313
Subject(s) - biomarker , medicine , oncology , surrogate endpoint , placebo , clinical endpoint , clinical trial , pathology , biology , biochemistry , alternative medicine
Training data NL 76 75.8 (6) 53 9.5 (4.4) 7358 (762) 1.24 (0.2) MCI conv 57 72.7 (7) 42 20.3 (6.8) 6464 (861) 1.44 (0.2) AD 21 72.7 (10) 43 29.3 (8.7) 5872 (988) 1.4 (0.2) Testing data NL 30 77.5 (6) 43 11.1 (4.1) 7137 (800) 1.03 (0.14) MCI stable 164 73.4 (6.9) 39 15.5 (6.19) 7028 (1009) 1.28 (0.2) MCI conv 71 75.4 (6.7) 40 21.3 (5.4) 5882 (8644) NA AD 98 74.7 (8) 40 28.6 (8) 5709 (1105) 1.59 (0.1) Poster Presentations: Saturday, July 15, 2017 P36